REVIEW pharmacotherapy Peyronie's disease

Cover Page

Abstract


Peyronie's disease - is a local idiopathic fibrosis developing in the tunica of the penis, which subsequently leads to a curvature of the penis and sexual dysfunction. Therapy is conducted in the chronic stage, or stage of the stabilization process, especially when there are signs of calcification plaques, found to be ineffective. The main goal of therapy is aimed at stopping the inflammatory process and the maximum preservation of tunica albuginea from defeat indurative process and the reduction of pain syndrome arising during erection. Conservative therapy of Peyronie's disease, currently, is shown in the acute stage, which lasts from 6 to 18 months.

S K Karaguzhin

Email: sabirjan35@yandex.ru

V A Kovalev

S V Koroleva

A N Abdulkhamidov

S K Karaguzhin

V A Kovalev

S V Korolev

A N Abdulhamid

  1. Lue T.F, Gelbard M.K, Gueglio G, et al.. Peyronie's disease. In: Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R editor. Erectile dysfunction. First International Consultation on Erectile Dysfunction. Plymouth, United Kingdom: Plymbridge Distributors; 2000; p. 439-476.
  2. Hauck E.W, Schroeder-Printzen I, Weidner W. Konservative Therapie der Induratio penis plastica. Aktuel Urol. 2001;32:44-47.
  3. La Peyronie F. Sur quelques obstacles qui s'opposent a l'ejaculation naturelle de la semence. In Mein de l'Academie Royale de Chir. New Edn. Paris, 1743: 425 - 34.
  4. Steinberg C. A new method of treatment of Dupuytren's contacture. Med. Clin. N. Am. 1946; 30: 221-226.
  5. Scardino P.L, Scott W.W. The use of tocopherols in the treatment of Peyronie's Disease. Ann New York Acad Sci 1949; 52: 390 - 3.
  6. Gelbard M.K, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 1376 - 9.
  7. Zarafonetis C.D, Horrax T.M. Treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba). J Urol. 1959;81:770-772. 8.
  8. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA™) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530-536.
  9. Ralph D.J, Brooks M.D, Bottazzo G.F, Pryor J.P. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992;70:648-651. 10.
  10. Teloken C, Rhoden E.L, Grazziotin T.M, Da Ros C.T, Sogari P.R, Souto C.V. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999;162:2003-2005. 11.
  11. Biagotti G, Cavallini G. Acetyl-l-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88:63-67.
  12. Kadioglu A, Tefekli A, Köksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12:169-175.
  13. Safarinejad M.R. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int Impot Res. 2004;16:238-243. 16.
  14. Lemourt Oliva M, Filgueiras López E, Rodríguez Barroso A, González Oramas E, Bordonado R. Evalución clínica del uso propóleo en la enfermedad de Peyronie. Arch Esp Urol. 1998;51:171-176. 17.
  15. Lemourt Oliva M, Rodriguez Barroso A, Bordonado Ramirez R, Gonzalez Oramas E, Molina Castillo F. Estudio de dosis con Propóleo en la enfermedad de Peyronie. Arch Esp Urol. 2003;56:814-819.
  16. Levine L.A, Merrick P.F, Lee R.C. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol. 1994;151:1522-1524. 19.
  17. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology. 1998;51:620-626.
  18. Wegner H.E, Andresen R, Knispel H.H, Miller K. Treatment of Peyronie's disease with local interferon-alpha2b. Eur Urol. 1995;28:236-240. 21.
  19. Hellstrom W, Eichelberg C, Pryor J.L, et al.. A single-blind, multi-center, placebo-controlled study to assess the safety and efficacy of intralesional interferon alpha-2b in the non-surgical treatment of Peyronie's disease. J Urol. 2003;169:274; 22.
  20. Riedl C, Sternig P, Gallé G, et al.. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005;48:656-661.
  21. Горячев И. А., Афтенко Т. В., Богданов В. В., Жиганова Т. П., Богданова Т. А. Комбинированное лечение болезни Пейрони с использованием низкоинтенсивного лазерного излучения. Учен. зап., С.-Петерб. гос. мед. ун-та им. И. П. Павлова. 1988; №2: 85.
  22. Мазо В. Е. Лазеромагнитная терапия болезни Пейрони. Применение лазеров в медицине и хирургии .Тез. междунар. симп. по хирургии и меди-цине., Л;1988: 410-411.
  23. Riedl C.R, Plas E, Engelhardt P, Daha K, Pflüger H. Iontophoresis for treatment of Peyronie's disease. J Urol. 2000;163:95-99. 26.
  24. Di Stasi S.M, Giannantoni A, Capelli G, et al.. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int. 2003;91:825-829.
  25. Levine L.A, Estrada C.R, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003;169:1775-1778.
  26. Bellorofonte C., Ruoppolo M. et al. Possibility of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis. Arch Ital Urol Nefrol Androl 1989; 61(4): 417-422.
  27. Hauck E.W, Mueller U.O, Bschleipfer T, Schmelz H.U, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol. 2004;171:740-745.
  28. Кучерский В.М., Алферов Б.В., Москвин М.И. Гирудотерапия болезни Пейрони. Андрология и генитальная хирургия (тезисы научных трудов), М., 2002: 113.

Views

Abstract - 227

PDF (Russian) - 146

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2010 Karaguzhin S.K., Kovalev V.A., Koroleva S.V., Abdulkhamidov A.N., Karaguzhin S.K., Kovalev V.A., Korolev S.V., Abdulhamid A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.